CIK 0001824893
- Non-accelerated filer
- Smaller reporting company
Surrozen, Inc./DE
Sign in to watch- Ticker
- SRZN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 301374889
- Phone
- +1 650-475-2820
- Business address
- 171 OYSTER POINT BLVD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Consonance-HFW Acquisition Corp.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy 10% owner bought 18,856 shares at an average $23.59 ($444,844)
- 4 Open-market buy 10% owner bought 9,357 shares at an average $21.65 ($202,534)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Open-market buy 10% owner bought 32,507 shares at an average $19.74 ($641,597)
- 4 Open-market buy Director bought 32,507 shares at an average $19.74 ($641,597)
- 4 Open-market buy Director bought 17,993 shares at an average $19.86 ($357,353)
- 4 Open-market buy 10% owner bought 17,993 shares at an average $19.86 ($357,353)
- 4 Open-market buy 10% owner bought 15,100 shares at $19.89 ($300,297)
- 4 Open-market buy Director bought 15,100 shares at $19.89 ($300,297)
- 4 Open-market sale Exec. Vice President, Research sold 1,118 shares at $19.87 ($22,209)
- 4 Open-market sale Chief Operating Officer sold 1,566 shares at $19.87 ($31,109)
- 4 Grant or award Exec. Vice President, Research acquired 1,666 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 1,666 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 1,553 shares (grant or award)
- 4 Open-market buy Director bought 36,150 shares at an average $19.22 ($694,850)
- 4 Open-market buy 10% owner bought 36,150 shares at an average $19.22 ($694,850)
Page 2 of 10 · 189 filings